Latest Content

How Circulating Tumor Cell Count Can Inform Prostate Cancer Treatment

November 18th 2024, 4:00pm

By Alex Biese

Article

An expert explained how circulating tumor cell count can identify possible clinical trial participants.

Blenrep-Based Combo Provides Survival Benefit in Relapsed/Refractory Multiple Myeloma

November 18th 2024, 2:00pm

By Darlene Dobkowski, MA

Article

Findings from a phase 3 trial with Blenrep, Velcade and dexamethasone in relapsed/refractory multiple myeloma will be presented at an upcoming conference.

Nurse Champions of Patient Safety, Dignity and Leadership

November 17th 2024, 7:00pm

By Erin Longstreth-Papsun, M.S.N., RN, OCN

Article

Three nurses—Maria Hicinbothem, Wandaris Ortiz, and Sandi Wetherbee—are being celebrated for their exceptional dedication to patient care, safety and advocacy.

FDA Receives Application for Dato-DXd Treatment in EGFR-Mutated NSCLC

November 16th 2024, 7:00pm

By Ryan Scott

Article

For patients with previously treated EGFR-mutated NSCLC, a new BLA has been submitted to the FDA seeking the accelerated approval of Dato-DXd.

I’ve Decided What My Legacy Is During Colon Cancer

November 16th 2024, 3:00pm

By Lauryn Cooney

Article

When I was diagnosed with colon cancer, I had a hard time deciding what my legacy should be, but once I realized what it was, I had to keep working hard for it.

FDA Approves Revuforj for Relapsed/Refractory Acute Leukemia Subset

November 15th 2024, 9:36pm

By Darlene Dobkowski, MA

Article

Revuforj was approved by the FDA for adults and children with relapsed/refractory acute leukemia with a KMT2A translocation.

Anti-TIGIT Therapy-Based Treatment Combo Did Not Improve Survival in Extensive-Stage SCLC

November 15th 2024, 8:00pm

By Caroline Seymour

Article

The anti-TIGIT therapy, vibostolimab, plus Keytruda and chemotherapy did not improve overall survival versus Tecentriq plus chemotherapy in extensive-stage small cell lung cancer.

FDA Approves Danziten for Leukemia Subset That Does Not Require Fasting

November 15th 2024, 6:00pm

By Darlene Dobkowski, MA

Article

Danziten, a new formulation of nilotinib, may improve treatment adherence in patients with Philadelphia chromosome-positive chronic myeloid leukemia.

Quincy Jones Died of Cancer, Dwayne Johnson Connects with a Fan with Cancer and More

November 15th 2024, 4:00pm

By Alex Biese

Article

From producer Quincy Jones’ death from pancreatic cancer to an inspiring moment between The Rock and a fan at a store, here’s what’s happening in the cancer space this week.

Treatment Options Are Not ‘One-Size-Fits-All’ in Head and Neck Cancers

November 15th 2024, 2:00pm

By Ashley Chan

Video

In patients with oropharyngeal cancer, deciding whether radiation therapy or surgery is the best option depends on their lifestyle and their values.

Optune Plus Temodar and Keytruda May Result in Brain Tumor Control

November 14th 2024, 10:00pm

By Ariana Pelosci

Article

Patients with glioblastoma experienced tumor control after complete in-situ vaccination and anti-PD-1 immunotherapy, researchers have reported.

ICI Response May Predict Relapse-Free Survival in Liver Cancer

November 14th 2024, 8:00pm

By Alex Biese

Article

Immune checkpoint inhibitor tumor regression may indicate which patients with hepatocellular carcinoma experience improved relapse-free survival.

Taking Time to ‘Smell the Roses’

November 14th 2024, 6:00pm

By Jane Biehl Ph.D.

Article

I spent my life racing against time, until my cancer diagnosis forced me to hit the brakes.

Addressing Pros and Cons of CAR-T Cell Therapy in Melanoma

November 14th 2024, 4:00pm

By Spencer Feldman

Video

The advantages and disadvantages of CAR-T cell therapy should be carefully thought about for patients with melanoma.

A Phase 3 Trial of Amezalpat in Advanced Liver Cancer Receives Study May Proceed Letter

November 14th 2024, 2:00pm

By Ryan Scott

Article

For unresectable or metastatic liver cancer, the TPST-1120-301 trial of amezalpat combination therapy has received a “Study May Proceed” letter from the FDA.